Cantor Fitzgerald Reiterates Buy Rating on Atrium Therapeutics
Cantor Fitzgerald maintains its optimistic view on Atrium Therapeutics with a $25 price target, a 95.16% upside from the current price.
Key Points
- Cantor Fitzgerald reiterated its buy rating for Atrium Therapeutics, setting a $25 price target on June 18, 2026.
- Cantor Fitzgerald's $25 price target implies 95.16% upside from Atrium Therapeutics, Inc.'s ($RNA) current $12.81 share price.
- Atrium Therapeutics, trading at $12.48, has a market cap of about $213.5 million and is focused on RNA therapeutics for cardiomyopathies.
- Recent insider buying included CEO Kathleen Gallagher acquiring 102,500 shares on April 20, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Cantor Fitzgerald reiterated its buy rating for Atrium Therapeutics, Inc. (NasdaqGS:RNA) on June 18, 2026. The firm set a price target of $25, signaling confidence in the biopharmaceutical company's future prospects.
Atrium Therapeutics, Inc. Stock Down 6.1%
Shares of NasdaqGS:RNA traded near $12.48. Atrium Therapeutics has a market cap of approximately $213.5 million. The company focuses on RNA-based therapies for cardiomyopathies, with its stock reaching a 52-week high of $16.77 and a low of $11.4. The stock's 50-day moving average is $13.02, while the 200-day moving average is $13.36. The company is not currently profitable, reflected in its negative forward P/E ratio.
Recent Earnings
For its latest quarter, Atrium Therapeutics reported revenue of $36.68 million, showing a growth of 11.5%. Despite this, the company recorded a net margin of -160%, indicating it is still in the development phase with substantial costs. The next earnings report is expected on May 11, 2026.
Insider Buying and Selling at Atrium Therapeutics, Inc.
On April 20, 2026, several insiders purchased shares of Atrium Therapeutics. CEO Kathleen Gallagher bought 102,500 shares, while Chief Strategy Officer Rocio Martin acquired 60,000 shares. Chief Medical Officer Steven Hughes, Chief Corporate Affairs Officer Stephanie Kenney, and CFO Brendan Winslow each purchased shares, showing insider confidence in the company's direction.
Analysts Set New Price Targets
On June 18, 2026, Cantor Fitzgerald reiterated its buy rating and set a $25 price target for Atrium Therapeutics. This aligns with other analysts like Leerink Partners and Wells Fargo, who also initiated buy ratings with the same target price earlier this year. The consensus target mean price stands at $25, with two analysts currently covering the stock.
About Atrium Therapeutics
Atrium Therapeutics, Inc., headquartered in San Diego, California, is a biotechnology company specializing in RNA therapeutics aimed at treating cardiomyopathies. Led by CEO Kathleen P. Gallagher, the firm is developing therapies like ATR 1072 and ATR 1086, which target genetic conditions affecting the heart. Established in 2025, the company is part of the healthcare sector, with a focus on innovative treatments for cardiac diseases.
Bottom Line
Cantor Fitzgerald's reiterated buy rating and $25 price target reflect a positive outlook on Atrium Therapeutics' potential in RNA therapeutics. Investors watch these analyst ratings closely, as they provide insights into market expectations. However, it's important to remember that these ratings are based on past performance and projections, which might not reflect current market conditions.
Get Atrium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RNA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.